Aurobindo Pharma has reported results for the quarter and year ended March 31, 2012.
The company’s net profit for the fourth quarter ended March 31, 2012 fell 33.70% to Rs 87.91 crore as compared to Rs 132.59 crore for the quarter ended March 31, 2011. However, the total income has increased by 3.51% to Rs 1100.41 crore for the quarter under review from Rs 1063.10 crore for the corresponding quarter of the previous year.
For the year ended March 31, 2012, the company reported a net loss of Rs 42.61 crore as compared to net profit of Rs 593.80 crore for the previous year. However, the company’s total income has increased by 3.74% to Rs 4300.51 crore for the year from Rs 4145.63 crore in the previous year.
On consolidated basis, the Group’s net loss after taxes and minority interest stood at Rs 123.51 crore for the year under review as compared to net profit of Rs 563.45 crore for the period ago. However, its total income has increased by 5.60% to Rs 4652.10 crore for the year ended March 31, 2012 from Rs 4405.36 crore in the previous year.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |